Stability engineering of the human antibody repertoire (Q26859495)

Development trends for human monoclonal antibody therapeutics

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Aggregation events occur prior to stable intermediate formation during refolding of interleukin 1beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Recombinant protein folding and misfolding in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Detection and prevention of protein aggregation before, during, and after purification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Aggregation, stability, and formulation of human antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Biophysical properties of human antibody variable domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

General strategy for the generation of human antibody variable domains with increased aggregation resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

A broad range of Fab stabilities within a host of therapeutic IgGs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Navigating the folding routes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Amyloid-like fibrils of ribonuclease A with three-dimensional domain-swapped and native-like structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Protein folding and misfolding

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Protein aggregation and its inhibition in biopharmaceutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Effects of protein aggregates: an immunologic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

The importance of sequence diversity in the aggregation and evolution of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Formulation and manufacturability of biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Isotype selection in antibody engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Potent antibody therapeutics by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Human IgG2 antibodies display disulfide-mediated structural isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Free sulfhydryl measurement as an indicator of antibody stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Engineered human antibody constant domains with increased stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Repertoires of aggregation-resistant human antibody domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Antibody structure, instability, and formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Mechanically-induced aggregation of the monoclonal antibody cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Formulation and delivery issues for monoclonal antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Expression, purification and characterization of recombinant interleukin-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Biotechnology applications of amino acids in protein purification and formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Optimization of the antibody C(H)3 domain by residue frequency analysis of IgG sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Structure-based stability engineering of the mouse IgG1 Fab fragment by modifying constant domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal Fc receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Engineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Aggregation-prone motifs in human immunoglobulin G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Design of therapeutic proteins with enhanced stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Naturally occurring antibodies devoid of light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Selection and identification of single domain antibody fragments from camel heavy-chain antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Solution structure of a llama single-domain antibody with hydrophobic residues typical of the VH/VL interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

'Camelising' human antibody fragments: NMR studies on VH domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Rearrangement of the former VL interface in the solution structure of a camelised, single antibody VH domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Optimal design features of camelized human single-domain antibody libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Structural analysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR and unusual mammalian immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Replacing the complementarity-determining regions in a human antibody with those from a mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Designed to be stable: crystal structure of a consensus ankyrin repeat protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Stability engineering of antibody single-chain Fv fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Transfer of engineered biophysical properties between different antibody formats and expression systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Peptide aggregation in neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Native protein sequences are close to optimal for their structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Proteolytic selection for protein folding using filamentous bacteriophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Crystal structure of the two N-terminal domains of g3p from filamentous phage fd at 1.9 A: evidence for conformational lability

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Rapid prediction of expression and refolding yields using phage display.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Thermodynamically stable aggregation-resistant antibody domains through directed evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Engineered single-domain antibodies with high protease resistance and thermal stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Disulfide linkage engineering for improving biophysical properties of human VH domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Sequence determinants of protein aggregation in human VH domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Toward aggregation-resistant antibodies by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Selection of human antibody fragments by phage display

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Engineering Aggregation Resistance in IgG by Two Independent Mechanisms: Lessons from Comparison of Pichia pastoris and Mammalian Cell Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Biophysical Properties of Camelid VHHDomains Compared to Those of Human VH3 Domains†

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029

Sequence statistics reliably predict stabilizing mutations in a protein domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.11.029